Aurigene Oncology

Executive Summary

Aurigene Oncology is a clinical-stage biopharmaceutical company based in Bangalore, India, dedicated to discovering and developing novel cancer therapeutics. Founded in 2001, the company employs over 450 scientists and leverages deep expertise in oncology and immunology to create small molecule drugs targeting difficult-to-drug pathways. Its pipeline includes next-generation mechanisms such as degraders, bispecifics, and antibody-drug conjugates (ADCs), with a focus on both proprietary and partnered programs. Aurigene has advanced multiple candidates into Phase I clinical trials, targeting a range of solid tumors and hematological malignancies. The company's strategic partnerships with global pharmaceutical firms provide validation and non-dilutive funding, supporting its pipeline development without reliance on public markets. With a strong research foundation and a diversified portfolio, Aurigene is positioned to address key unmet needs in oncology, particularly in areas where conventional therapies have limited efficacy.

Upcoming Catalysts (preview)

• TBDPhase I data readout for lead degraders program40% success
• TBDIND filing for next-generation ADC candidate50% success
• TBDNew partnership or licensing deal for bispecific platform60% success